Table 2 Frequency of various treatment-emergent comorbid events a in insured patients initiating PEG-IFN-alfa and ribavirin treatment for chronic HCV infection
Variable | No. (%) with treatment-emergent comorbid event in the preindex period | No. (%) with treatment-emergent comorbid event in the postindex period | No. (%) diagnosed with a new treatment-emergent comorbid event in the postindex periodb |
|---|---|---|---|
(n = 1269) | (n = 1269) | (n = 1269) | |
Any treatment-related comorbid event | 803 (63.3) | 923 (72.7) | 782 (61.6) |
Blood | 182 (14.3) | 523 (41.2) | 446 (35.2) |
Anemia | 147 (11.6) | 461 (36.3) | 371 (29.2) |
Neutropenia | 18 (1.42) | 144 (11.4) | 139 (11.0) |
Thrombocytopenia | 46 (3.62) | 101 (7.96) | 85 (6.70) |
Gastrointestinal | 114 (8.98) | 175 (13.8) | 152 (12.0) |
Nausea/vomiting | 78 (6.15) | 124 (9.77) | 106 (8.35) |
Diarrhea | 55 (4.33) | 75 (5.91) | 63 (4.96) |
Endocrine | 317 (25.0) | 354 (27.9) | 154 (12.1) |
Diabetes | 214 (16.9) | 217 (17.1) | 61 (4.81) |
Hyperthyroidism | 20 (1.58) | 30 (2.36) | 26 (2.05) |
Hypothyroidism | 117 (9.22) | 164 (12.9) | 88 (6.93) |
Psychiatric | 262 (20.7) | 375 (29.6) | 255 (20.1) |
Depression | 181 (14.3) | 266 (21.0) | 146 (11.5) |
Anxiety disorders | 48 (3.78) | 54 (4.26) | 31 (2.44) |
Bipolar disorders | 22 (1.73) | 27 (2.13) | 17 (1.34) |
Insomnia | 82 (6.46) | 143 (11.3) | 114 (8.98) |
Skin and subcutaneous | 59 (4.65) | 119 (9.38) | 111 (8.75) |
Alopecia | 11 (0.87) | 17 (1.34) | 15 (1.18) |
Skin rash | 49 (3.86) | 103 (8.12) | 97 (7.64) |
Other disorders | 383 (30.2) | 423 (33.3) | 311 (24.5) |
Dyspnea | 91 (7.17) | 98 (7.72) | 76 (5.99) |
Fatigue | 270 (21.3) | 319 (25.1) | 208 (16.4) |
Headache | 96 (7.57) | 100 (7.88) | 75 (5.91) |